1 Erratum to: Clin Pharmacokinet DOI 10.1007/s40262-016-0458-4

Figures 2 and 3, and their corresponding legends were incorrect and were corrected in this erratum.

Figures 2 and 3 should appear as follows:

Fig. 2
figure 2

Individual analyte parameter ratios for dolutegravir (a) and doravirine (b) with geometric mean ratios and 90% confidence intervals following multiple-dose administration with and without the additional treatment [doravirine and dolutegravir, respectively (per-protocol population)]. AUC 0–24 area under the plasma concentration–time curve from dosing to 24 h post-dose, C 24 concentration 24 h post-dose, C max maximum concentration

Fig. 3
figure 3

Arithmetic mean steady-state doravirine plasma concentration profile with and without co-administration with dolutegravir: a linear scale (±SD) and b semi-log scale, SD standard deviation